Oxford Biomedica PLC Oxford Biomedica Notes Homology Q2 Report (1472W)
August 16 2022 - 1:00AM
UK Regulatory
TIDMOXB
RNS Number : 1472W
Oxford Biomedica PLC
16 August 2022
Oxford Biomedica notes Homology Medicines' quarterly report and
confirms financials for Oxford Biomedica Solutions LLC are in line
with expectations
Oxford, UK - 16 August 2022: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Company"), a leading gene and cell
therapy group, notes the release of Homology Medicines'
("Homology") quarterly report for the three months ended 30 June
2022. Financial information on Oxford Biomedica Solutions LLC
("Oxford Biomedica Solutions") contained within Homology's 10-Q is
in line with Company expectations. To view Homology's announcement
see: Form 10-Q .
Oxford Biomedica Solutions, 20% owned by Homology, is a US-based
full scope, AAV manufacturing and innovation business offering a
unique 'Plug & Play' platform and fully integrated end-to-end
capabilities, including from vector design and process development
through to clinical trials.
Oxford Biomedica Solutions has a robust business pipeline and
maintains its financial guidance. The Company is committed and
confident about securing two new Adeno-Associated Virus (AAV)
customer partnerships by the end of calendar year 2022.
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E:
oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Matthew Cole
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector
specialist focused on delivering life changing therapies to
patients.
Oxford Biomedica plc and its subsidiaries (the Group) work
across key viral vector delivery systems including those based on
lentivirus, adeno-associated virus (AAV) and adenovirus, providing
innovative solutions to cell and gene therapy biotechnology and
biopharma companies for their process development, analytical
development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector(R)
platform, which the Group leverages to develop product candidates
in-house, before seeking partners to take the products into
clinical trials.
Oxford Biomedica is based across several locations and
headquartered in Oxfordshire, UK. In early 2022, the Group
established Oxford Biomedica Solutions, a new US based subsidiary
AAV manufacturing and innovation business, based near Boston,
US.
Oxford Biomedica employs more than 940 people. Further
information is available at www.oxb.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUNOVRUKUWARR
(END) Dow Jones Newswires
August 16, 2022 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024